Development of a Nanoemulsion Adjuvant with a Vaccine for Pandemic Influenza

Information

• Research Project
• 8751859

• ApplicationId

  8751859

• Core Project Number

  N01AI000000

• Full Project Number

  272201300028C-0-0-1

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  9/30/2013 - 11 years ago

• Project End Date

  9/29/2016 - 8 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2013

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• NANOBIO, LLC

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants through immunological characterization studies and lead compound optimization, up to and including IND-enabling studies, all towards licensure for human use. Adjuvants will be studied with currently licensed or new investigational vaccines to protect against infection by NIAID emerging and re-emerging infectious disease pathogens.

IC Name

• Activity

  N01

• Administering IC

  AI

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  5516166

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  855

• Ed Inst. Type

• Funding ICs

  NIAID:5516166\

• Funding Mechanism

  Non SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  NANOBIO CORPORATION

• Organization Department

• Organization DUNS

  177653487

• Organization City

  ANN ARBOR

• Organization State

  MI

• Organization Country

  UNITED STATES

• Organization Zip Code

  481052965

• Organization District

  UNITED STATES